(Q36556505)

14 August 2017

1 reference

title

Drug-target residence time and its implications for lead optimization (English)

1 reference

14 August 2017

1 reference

Robert A Copeland

1

1 reference

14 August 2017

David L Pompliano

series ordinal

2

1 reference

14 August 2017

Thomas D Meek

series ordinal

3

1 reference

14 August 2017

publication date

4 August 2006

1 reference

Nature Reviews Drug Discovery

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

9

1 reference

14 August 2017

page(s)

730-739

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2082

14 August 2017

exact match

0 references

cites work

Efficacy at G-protein-coupled receptors

1 reference

Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model

31 March 2020

1 reference

Biochemical mechanisms of drug action: what does it take for success?

31 March 2020

1 reference

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

31 March 2020

1 reference

Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants

31 March 2020

1 reference

Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.

31 March 2020

1 reference

Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis

31 March 2020

1 reference

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

31 March 2020

1 reference

Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design

31 March 2020

1 reference

Characteristic physical properties and structural fragments of marketed oral drugs.

31 March 2020

1 reference

Steroid 5alpha-reductase inhibitors in androgen-dependent disorders.

31 March 2020

1 reference

In vivo time-dependent inhibition of human steroid 5 alpha-reductase by finasteride.

31 March 2020

1 reference

Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase

31 March 2020

1 reference

Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor

31 March 2020

1 reference

A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesar

31 March 2020

1 reference

Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?

31 March 2020

1 reference

Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban

31 March 2020

1 reference

Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated

31 March 2020

1 reference

Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia

31 March 2020

1 reference

Action of atypical antipsychotics

31 March 2020

1 reference

Action of atypical antipsychotics

31 March 2020

1 reference

A novel N-methyl-D-aspartate receptor open channel blocker with in vivo neuroprotectant activity

31 March 2020

1 reference

Paradigm shift in NMDA receptor drug development

31 March 2020

1 reference

Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase

31 March 2020

1 reference

Kinetic exclusion assay technology: characterization of molecular interactions

31 March 2020

1 reference

Optical biosensors in drug discovery

31 March 2020

1 reference

In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication

31 March 2020

1 reference

Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2082

1 reference

14 August 2017

1 reference